SG Americas Securities LLC Sells 2,500 Shares of Silence Therapeutics Plc (NASDAQ:SLN)
SG Americas Securities LLC Sells 2,500 Shares of Silence Therapeutics Plc (NASDAQ:SLN)
SG Americas Securities LLC lessened its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN – Get Rating) by 2.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 98,953 shares of the company's stock after selling 2,500 shares during the period. SG Americas Securities LLC owned 0.28% of Silence Therapeutics worth $977,000 at the end of the most recent reporting period.
根据SG Americas Securities LLC向美国证券交易委员会发布的最新披露，SG Americas Securities LLC在第三季度将其持有的Silence Therapeutics plc（纳斯达克股票代码：SLN — Get Rating）的该基金在此期间出售了2,500股股票后，拥有该公司98,953股股票。截至最近报告期末，SG Americas Securities LLC拥有Silence Therapeutics0.28％的股份，价值97.7万美元。
Separately, Citadel Advisors LLC bought a new stake in shares of Silence Therapeutics during the second quarter worth $136,000.
另外，Citadel Advisors LLC在第二季度购买了Silence Therapeutics的新股份，价值13.6万美元。
Silence Therapeutics Stock Down 3.6 %
沉默疗法股价下跌3.6％
Silence Therapeutics stock opened at $13.02 on Thursday. Silence Therapeutics plc has a 12-month low of $7.80 and a 12-month high of $23.23. The business's 50-day simple moving average is $14.69 and its 200 day simple moving average is $12.10. The stock has a market cap of $467.26 million, a price-to-earnings ratio of -8.57 and a beta of 0.99.
Silence Therapeutics的股票周四开盘价为13.0Silence Therapeutics plc创下12个月低点7.80美元，12个月高点为23.23美元。该公司的50天简单移动平均线为14.69美元，其200天简单移动平均线为12.10美元。该股的市值为4.6726亿美元，市盈率为-8.57，beta值为0.99。
Wall Street Analyst Weigh In
华尔街分析师权衡一下
Several brokerages have recently commented on SLN. Morgan Stanley started coverage on Silence Therapeutics in a report on Friday, December 9th. They set an "equal weight" rating and a $18.00 target price on the stock. Chardan Capital decreased their price target on Silence Therapeutics from $33.00 to $29.00 and set a "buy" rating on the stock in a report on Thursday, November 17th. Finally, HC Wainwright decreased their price target on Silence Therapeutics from $95.00 to $80.00 and set a "buy" rating on the stock in a report on Tuesday, December 6th.
几家经纪商最近对SLN发表了评论。摩根士丹利在12月9日星期五的一份报告中开始报道Silence Therapeutics。他们为该股设定了 “同等权重” 评级和18.00美元的目标价格。Chardan Capital将Silence Therapeutics的目标股价从33.00美元下调至29.00美元，并在11月17日星期四的一份报告中对该股设定了 “买入” 评级。最后，HC Wainwright在12月6日星期二的一份报告中将Silence Therapeutics的目标股价从95.00美元下调至80.00美元，并对该股设定了 “买入” 评级。
About Silence Therapeutics
关于 Silence Ther
(Get Rating)
（获取评分）
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Silence Therapeutics plc是一家生物技术公司，专注于血液学、心血管和其他罕见和代谢适应症领域的新型核糖核酸（RNA）疗法的发现和开发。该公司的平台包括mRNAI GalNAC寡核苷酸发现平台，该平台旨在准确靶向肝脏中的特定疾病相关基因。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Silence Therapeutics (SLN)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- 免费获取 StockNews.com 关于 Silence Therapeutics (SLN) 的研究报告的副本
- 宝洁公司收益：一场值得一试的赌博
- 股市下滑，经济报告描绘了经济的阴暗前景
- Nu Holdings 的股票与沃伦·巴菲特有什么关系？
- J.B. Hunt 持平，物流公司成为人们关注的焦点
- 英特尔股票即将爆发吗？
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Silence Therapeutics 每日的新闻 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Silence Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。